Background
Methods
NET-QUBIC assessment protocol
Study follow-up procedures
Statistical analyses
Results
HNC patients (n = 739) | Informal caregivers (n = 262) | |
---|---|---|
Mean age ± SD | 63.2 ± 9.7 | 58.8 ± 11.6 |
Sex, n (%) | ||
Men | 549 (74%) | 70 (27%) |
Women | 190 (26%) | 192 (73%) |
Education level, n (%)a | ||
Low | 279 (43%) | 82 (37%) |
Middle | 171 (26%) | 63 (28%) |
High | 198 (31%) | 78 (35%) |
Living situation, n (%)b | ||
Living alone | 163 (25%) | 8 (4%) |
Living with partner (with or without children) | 451 (69%) | 205 (91%) |
Other (e.g. living with children, living with parents or assisted living | 35 (5%) | 12 (5%) |
Tumor location, n (%) | ||
Oral Cavity | 199 (27%) | |
Oropharynx | 262 (36%) | |
Hypopharynx | 52 (7%) | |
Larynx | 205 (28%) | |
Unknown primary | 21 (3%) | |
Clinical disease Stage, n (%) | ||
Stage 0/Ic | 163 (22%) | |
Stage II | 132 (18%) | |
Stage III | 127 (17%) | |
Stage IV | 317 (43%) | |
Type of treatment, n (%)d | ||
Single treatment | ||
Surgery | 152 (21%) | |
Radiotherapy | 241 (33%) | |
Combination treatment | ||
Chemoradiotherapy | 215 (29%) | |
Surgery and radiotherapy | 106 (14%) | |
Surgery and chemoradiotherapy | 23 (3%) | |
Othere | 1 (0.1%) | |
WHO performance, n (%) | ||
Able to carry out normal activity | 507 (69%) | |
Restricted in physically strenuous activity but ambulatory and able to carry out light work | 191 (26%) | |
Ambulatory and capable of all self-care but unable to carry out any work | 40 (5%) | |
Capable of only limited self-care | 1 (0.1%) | |
Completely disabled | 0 (0%) | |
Comorbidity, n (%)f | ||
None | 204 (29%) | |
Mild | 264 (38%) | |
Moderate | 155 (22%) | |
Severe | 76 (11%) | |
HPV-status (oropharynx cancer only), n (%)g | ||
Positive | 99 (43%) | |
Negative | 130 (57%) | |
Baseline smoking status, n (%)h | ||
Daily smoker | 127 (22%) | 38 (17%) |
Not a daily smoker | 445 (78%) | 187 (83%) |
Baseline alcohol consumption, n (%)i | ||
Excessive alcohol consumption | 129 (22%) | 25 (11%) |
No excessive alcohol consumption | 445 (78%) | 200 (89%) |
Relation informal caregiver – patient, n (%)j | ||
Partner | 219 (84%) | |
Daughter/son | 31 (12%) | |
Other (i.e. sibling, friend, ex-partner) | 10 (4%) |
Study retention and attrition
Factors associated with study retention
PROMsa Yes N = 605 | PROMsa No N = 134 | P-value | Fieldwork Yes N = 578 | Fieldwork No N = 161 | P-value | Biobank Yes N = 718 | Biobank No N = 21 | P-value | ||||
Gender, n (%) | ||||||||||||
Men | 450 (74%) | 99 (74%) | 0.90 | 438 (76%) | 111 (69%) | 0.08 | 536 (75%) | 13 (62%) | 0.19 | |||
Women | 155 (26%) | 35 (26%) | 140 (24%) | 50 (31%) | 182 (25%) | 8 (38%) | ||||||
Age, mean ± SD years | 63.5 ± 9.5 | 62.0 ± 10.9 | 0.14 | 63.6 ± 9.3 | 61.9 ± 11.0 | 0.06 | 63 ± 9.7 | 62 ± 11.3 | 0.57 | |||
Tumor location, n (%) | 0.29 | 0.33 | 0.47c | |||||||||
Oral Cavity | 168 (28%) | 31 (23%) | 147 (25%) | 52 (32%) | 191 (27%) | 8 (38%) | ||||||
Oropharynx | 211 (35%) | 51 (38%) | 212 (37%) | 50 (31%) | 256 (36%) | 6 (29%) | ||||||
Hypopharynx | 38 (6%) | 14 (10%) | 38 (7%) | 14 (9%) | 52 (7%) | 0 (0%) | ||||||
Larynx | 169 (28%) | 36 27%) | 164 (28%) | 41 (25%) | 199 (28%) | 6 (29%) | ||||||
Unknown primary | 19 (3%) | 2 (1%) | 17 (3%) | 4 (2%) | 20 (3%) | 1 (5%) | ||||||
Clinical disease Stage, n (%) | 0.011 | 0.16 | 0.87c | |||||||||
0/I | 147 (24%) | 16 (12%) | 133 (23%) | 30 (19%) | 159 (22%) | 4 (19%) | ||||||
II | 108 (18%) | 24 (18%) | 94 (16%) | 38 (24%) | 129 (18%) | 3 (14%) | ||||||
III | 97 (16%) | 30 (22%) | 99 (17%) | 28 (17%) | 122 (17%) | 5 (24%) | ||||||
IV | 253 (42%) | 64 (48%) | 252 (44%) | 65 (40%) | 308 (43%) | 9 (43%) | ||||||
Treatment, n (%)b | 0.46 | 0.75 | 0.16 | |||||||||
Single treatment | 326 (54%) | 67 (50%) | 306 (53%) | 87 (54%) | 385 (54%) | 8 (38%) | ||||||
Combination treatment | 279 (46%) | 66 (50%) | 272 (47%) | 73 (46%) | 332 (46%) | 13 (62%) | ||||||
WHO performance, n (%) | 0.001 | 0.51 | 0.72 | |||||||||
Able to carry out normal activity | 426 (70%) | 81 (60%) | 394 (68%) | 113 (70%) | 493 (69%) | 14 (67%) | ||||||
Restricted in physically strenuous activity | 154 (25%) | 37 (28%) | 154 (27%) | 37 (23%) | 186 (26%) | 5 (24%) | ||||||
Ambulatory | 25 (4%) | 16 (12%) | 30 (5%) | 11 (5%) | 39 (5%) | 2 (10%) | ||||||
Comorbidity, n (%) | 0.003 | 0.63 | 0.30 | |||||||||
None | 180 (31%) | 24 (20%) | 164 (30%) | 40 (27%) | 200 (29%) | 4 (24%) | ||||||
Mild | 223 (39%) | 41 (34%) | 206 (37%) | 58 (39%) | 257 (38%) | 7 (41%) | ||||||
Moderate | 117 (20%) | 38 (31%) | 118 (21%) | 37 (25%) | 153 (22%) | 2 (12%) | ||||||
Severe | 57 (10%) | 19 (16%) | 62 (11%) | 14 (9%) | 72 (11%) | 4 (24%) | ||||||
Tumor biopsy Yes N = 142 | Tumor biopsy No N = 597 | P-value | Bloodd Yes N = 655 | Bloodd No N = 84 | P-value | Oral rinse Yes N = 650 | Oral rinse No N = 89 | P-value | Saliva Yes N = 436 | Saliva No N = 303 | P-value | |
Gender, n (%) | 0.17 | 0.52 | 0.29 | 0.23 | ||||||||
Men | 99 (70%) | 450 (75%) | 489 (75%) | 60 (71%) | 487 (75%) | 62 (70%) | 331 (76%) | 218 (72%) | ||||
Women | 43 (30%) | 147 (25%) | 166 (25%) | 24 (29%) | 163 (25%) | 27 (30%) | 105 (24%) | 85 (28%) | ||||
Age, mean ± SD years | 62.5 ± 10.0 | 63.4 ± 9.8 | 0.29 | 63.4 ± 9.6 | 62.3 ± 10.5 | 0.36 | 63.3 ± 9.6 | 62.9 ± 11.1 | 0.73 | 64.0 ± 8.9 | 62.2 ± 10.8 | 0.022 |
Tumor location, n (%) | 0.022 | 0.58 | 0.20 | 0.26 | ||||||||
Oral Cavity | 41 (29%) | 158 (26%) | 173 (26%) | 26 (31%) | 168 (26%) | 31 (35%) | 105 (24%) | 94 (31%) | ||||
Oropharynx | 56 (39%) | 206 (34%) | 232 (35%) | 30 (36%) | 229 (35%) | 33 (37%) | 166 (38%) | 96 (32%) | ||||
Hypopharynx | 16 (11%) | 36 (6%) | 47 (7%) | 5 (6%) | 49 (8%) | 3 (3%) | 31 (7%) | 21 (7%) | ||||
Larynx | 26 (18%) | 179 (30%) | 186 (28%) | 19 (23%) | 186 (29%) | 19 (21%) | 122 (28%) | 83 (27%) | ||||
Unknown primary | 3 (2%) | 18 (3%) | 17 (3%) | 4 (5%) | 18 (3%) | 3 (3%) | 12 (3%) | 9 (3%) | ||||
Clinical disease Stage, n (%) | 0.020 | 0.74 | 0.08 | 0.35 | ||||||||
0/I | 18 (13%) | 145 (24%) | 146 (22%) | 17 (20%) | 142 (22%) | 21 (24%) | 101 (23%) | 62 (20%) | ||||
II | 28 (20%) | 104 (17%) | 118 (18%) | 14 (17%) | 121 (19%) | 11 (12%) | 70 (16%) | 62 (20%) | ||||
III | 24 (17%) | 103 (17%) | 109 (17%) | 18 (21%) | 104 (16%) | 23 (26%) | 72 (17%) | 55 (18%) | ||||
IV | 72 (51%) | 245 (41%) | 282 (43%) | 35 (42%) | 283 (44%) | 34 (38%) | 193 (44%) | 124 (41%) | ||||
Treatment, n (%)b | 0.39 | 0.043 | 0.15 | 0.86 | ||||||||
Single treatment | 71 (50%) | 322 (54%) | 357 (55%) | 36 (43%) | 352 (54%) | 41 (46%) | 231 (53%) | 162 (54%) | ||||
Combination treatment | 71 (50%) | 274 (46%) | 297 (45%) | 48 (57%) | 297 (46%) | 48 (54%) | 205 (47%) | 140 (46%) | ||||
WHO performance, n (%) | 0.028 | 0.13 | 0.97 | 0.046 | ||||||||
Able to carry out normal activity | 86 (61%) | 421 (71%) | 456 (70%) | 51 (61%) | 445 (68%) | 62 (70%) | 309 (71%) | 198 (65%) | ||||
Restricted in physically strenuous activity | 43 (30%) | 148 (25%) | 166 (25%) | 25 (30%) | 169 (26%) | 22 (25%) | 110 (25%) | 81 (27%) | ||||
Ambulatory | 13 (9%) | 28 (5%) | 33 (5%) | 8 (10%) | 36 (6%) | 5 (6%) | 17 (4%) | 24 (8%) | ||||
Comorbidity, n (%) | 0.030 | 0.97 | 0.91 | 0.45 | ||||||||
None | 30 (21%) | 174 (31%) | 180 (29%) | 24 (31%) | 178 (29%) | 26 (32%) | 129 (31%) | 75 (27%) | ||||
Mild | 50 (36%) | 214 (38%) | 234 (38%) | 30 (38%) | 236 (38%) | 28 (35%) | 159 (38%) | 105 (38%) | ||||
Moderate | 41 (29%) | 114 (20%) | 139 (22%) | 16 (21%) | 137 (22%) | 18 (22%) | 85 (20%) | 70 (25%) | ||||
Severe | 19 (14%) | 57 (10%) | 68 (11%) | 8 (10%) | 67 (11%) | 9 (11%) | 46 (11%) | 30 (11%) |
PROMs Yes N = 228 | PROMs No N = 34 | P-value | Biobank Yes N = 238 | Biobank No N = 24 | P-value | |
---|---|---|---|---|---|---|
Gender, n (%) | ||||||
Men | 62 (27%) | 8 (24%) | 0.65 | 61 (26%) | 9 (38%) | 0.21 |
Women | 166 (73%) | 26 (76%) | 177 (74%) | 15 (63%) | ||
Age, mean ± SD years | 59.3 ± 11.3 | 55.7 ± 13.3 | 0.09 | 58.9 ± 11.7 | 57.7 ± 10.1 | 0.63 |
Relation informal caregiver – patienta, n (%) | 0.14b | 0.61b | ||||
Partner | 194 (85%) | 25 (76%) | 200 (84%) | 19 (83%) | ||
Daughter/son | 26 (11%) | 5 (15%) | 27 (11%) | 4 (17%) | ||
Other (i.e. sibling, friend, ex-partner) | 7 (3%) | 3 (9%) | 10 (4%) | 0 (0%) |
6 months follow-up | 1 year follow-up | 2 years follow-up | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Active patients N = 615 | Drop-outs (all) N = 124 | Drop-outs (excl. deceased) N = 93 | p-value active vs. drop-outs (all) | p-value active vs. drop-outs (deceased) | Active patients N = 552 | Drop-outs (all) N = 187 | Drop-outs (excl. deceased) N = 105 | p-value active vs. drop-outs (all) | p-value active vs. drop-outs (deceased) | Active patients N = 486 | Drop-outs (all) N = 253 | Drop-outs (excl. deceased) N = 122 | p-value active vs. drop-outs (all) | p-value active vs. drop-outs (deceased) | |
Gender, n (%) | |||||||||||||||
Men | 454 (74%) | 95 (77%) | 72 (77%) | 0.52 | 0.46 | 409 (74%) | 140 (75%) | 78 (74%) | 0.84 | 0.97 | 358 (74%) | 191 (75%) | 86 (70%) | 0.59 | 0.48 |
Women | 161 (26%) | 29 (23%) | 21 (23%) | 143 (26%) | 47 (25%) | 27 (26%) | 128 (26%) | 62 (25%) | 36 (30%) | ||||||
Age, mean ± SD years | 63.4 ± 9.6 | 62.6 ± 10.6 | 61.6 ± 10.9 | 0.41 | 0.15 | 63.3 ± 9.6 | 63.1 ± 10.3 | 62.3 ± 10.6 | 0.84 | 0.36 | 63.5 ± 9.7 | 62.8 ± 9.8 | 62.1 ± 10.3 | 0.35 | 0.17 |
Tumor location, n (%) | 0.82 | 0.94 | 0.46 | 0.49 | 0.011 | 0.65 | |||||||||
Oral Cavity | 165 (27%) | 34 (17%) | 23 (25%) | 146 (26%) | 53 (28%) | 24 (23%) | 126 (26%) | 73 (29%) | 35 (29%) | ||||||
Oropharynx | 219 (36%) | 43 (35%) | 32 (34%) | 197 (36%) | 65 (35%) | 36 (34%) | 174 (36%) | 88 (35%) | 39 (32%) | ||||||
Hypopharynx | 41 (7%) | 11 (9%) | 7 (8%) | 34 (6%) | 18 (10%) | 9 (9%) | 24 (5%) | 28 (11%) | 9 (7%) | ||||||
Larynx | 171 (28%) | 34 (27%) | 29 (31%) | 158 (29%) | 47 (25%) | 35 (33%) | 147 (30%) | 58 (23%) | 37 (30%) | ||||||
Unknown primary | 19 (3%) | 2 (2%) | 2 (2%) | 17 (3%) | 4 (2%) | 1 (1%) | 15 (3%) | 6 (2%) | 2 (2%) | ||||||
Clinical disease Stage, n (%) | 0.011 | 0.11 | < 0.001 | 0.12 | < 0.001 | 0.50 | |||||||||
0/I | 148 (24%) | 15 (12%) | 14 (15%) | 139 (25%) | 24 (13%) | 20 (19%) | 126 (26%) | 37 (15%) | 28 (23%) | ||||||
II | 113 (18%) | 19 (15%) | 15 (16%) | 106 (19%) | 26 (14%) | 17 (16%) | 94 (19%) | 38 (15%) | 22 (18%) | ||||||
III | 100 (16%) | 27 (22%) | 22 (24%) | 88 (16%) | 39 (21%) | 26 (25%) | 76 (16%) | 51 (20%) | 26 (21%) | ||||||
IV | 254 (41%) | 63 (51%) | 42 (45%) | 219 (40%) | 98 (52%) | 42 (40%) | 190 (39%) | 127 (50%) | 46 (38%) | ||||||
Type of treatment, n (%)a | 0.28 | 0.65 | 0.06 | 0.86 | 0.018 | 0.54 | |||||||||
Single treatment | 333 (54%) | 60 (49%) | 48 (52%) | 305 (55%) | 88 (47%) | 57 (54%) | 274 (56%) | 119 (47%) | 65 (53%) | ||||||
Combination treatment | 282 (46%) | 63 (51%) | 45 (48%) | 247 (45%) | 98 (53%) | 48 (46%) | 212 (44%) | 133 (53%) | 57 (47%) | ||||||
WHO performance, n (%) | < 0.001 | 0.018 | < 0.001 | 0.005 | < 0.001 | 0.042 | |||||||||
Able to carry out normal activity | 442 (72%) | 65 (52%) | 56 (60%) | 400 (72%) | 107 (57%) | 68 (65%) | 364 (75%) | 143 (57%) | 79 (65%) | ||||||
Restricted in physically strenuous activity | 148 (24%) | 43 (35%) | 28 (30%) | 136 (25%) | 55 (29%) | 27 (26%) | 107 (22%) | 84 (33%) | 35 (29%) | ||||||
Ambulatory | 25 (4%) | 16 (13%) | 9 (10%) | 16 (3%) | 25 (13%) | 10 (9%) | 15 (3%) | 26 (10%) | 8 (7%) | ||||||
Comorbidity, n (%) | 0.06 | 0.32 | 0.003 | 0.06 | < 0.001 | 0.016 | |||||||||
None | 179 (30%) | 25 (22%) | 21 (25%) | 166 (32%) | 38 (22%) | 21 (22%) | 149 (32%) | 55 (23%) | 25 (22%) | ||||||
Mild | 226 (39%) | 38 (34%) | 30 (36%) | 205 (39%) | 59 (34%) | 37 (38%) | 189 (41%) | 75 (32%) | 41 (37%) | ||||||
Moderate | 123 (21%) | 32 (29%) | 25 (30%) | 105 (20%) | 50 (29%) | 30 (31%) | 86 (19%) | 69 (29%) | 35 (31%) | ||||||
Severe | 59 (10%) | 17 (15%) | 8 (10%) | 49 (9%) | 27 (16%) | 9 (9%) | 39 (8%) | 37 (16%) | 11 (10%) |
6 months follow-up | 1 year follow-up | 2 years follow-up | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Active caregivers N = 172 | Drop-outs (all) N = 90 | Drop-outs (excl. With inactive patients) N = 58 | p-value active vs. drop-outs (all) | p-value active vs. drop-outs (excl. inactive) | Active caregivers N = 161 | Drop-outs (all) N = 101 | Drop-outs (excl. With inactive patients) N = 54 | p-value active vs. drop-outs (all) | p-value active vs. drop-outs (excl. inactive) | Active caregivers N = 136 | Drop-outs (all) N = 126 | Drop-outs (excl. With inactive patients) N = 57 | p-value active vs. drop-outs (all) | p-value active vs. drop-outs (excl. inactive) | |
Gender, n (%) | 0.76 | 0.32 | 0.77 | 0.40 | 0.51 | 0.75 | |||||||||
Men | 47 (27%) | 23 (26%) | 12 (21%) | 42 (26%) | 28 (28%) | 11 (20%) | 34 (25%) | 36 (29%) | 13 (23%) | ||||||
Women | 125 (73%) | 67 (74%) | 46 (79%) | 119 (74%) | 73 (72%) | 43 (80%) | 102 (75%) | 90 (71%) | 44 (77%) | ||||||
Age, mean ± SD years | 59.7 ± 10.9 | 57.1 ± 12.7 | 57.2 ± 11.6 | 0.09 | 0.14 | 60.0 ± 10.4 | 56.9 ± 13.0 | 56.2 ± 12.6 | 0.042 | 0.030 | 60.9 ± 9.9 | 56.5 ± 12.8 | 55.0 ± 12.2 | 0.002 | 0.002 |
Relation informal caregiver – patienta, n (%) | 0.09 | 0.58 | 0.25 | 0.93 | 0.09 | 0.26 | |||||||||
Partner | 151 (89%) | 68 (77%) | 48 (83%) | 140 (87%) | 79 (80%) | 46 (85%) | 121 (89%) | 98 (79%) | 46 (81%) | ||||||
Daughter/son | 16 (9%) | 15 (17%) | 7 (12%) | 15 (9%) | 16 (16%) | 6 (11%) | 11 (8%) | 20 (16%) | 7 (12%) | ||||||
Other (i.e. sibling, ex-partner)friend, | 5 (3%) | 5 (6%) | 3 (5%) | 6 (4%) | 4 (4%) | 2 (4%) | 4 (3%) | 6 (5%) | 4 (7%) |